Published in Cancer Weekly, April 27th, 2004
IR BioSciences Holdings, Inc., will license the use of its proprietary compound Homspera through this new entity for studies on the compound's efficacy in potentially treating adverse effects of cancer, cigarette smoking, influenza, SARS/Avian Flu, and HIV, among others.
The future studies are expected to be held at research labs located at Biopolis, a center for biomedical sciences located in close proximity to the National University of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.